stockrow
Friday 6 November 2026
Export PSNL’s income statement to Excel — free account
Personalis, Inc.
PSNL Healthcare Diagnostics & Research
Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024.
- Revenue
- +76.6%
- EPS
- −33.3%
- Free cash flow
- −15.5%
Quarter to September 2026, against a year earlier
15.81
0.26
+1.67%
Follow PSNL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.20 | 10.29 | 20.28 | 21.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(31.93) | (29.53) | (54.82) | (64.47) | |
P/B ratio |
2.72 | 2.61 | 6.01 | 8.21 | |
Price to Tangible BV |
2.72 | 2.61 | 6.01 | 8.21 | |
EV/Sales |
7.01 | 6.95 | 17.48 | 19.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.52) | (5.64) | (13.20) | (16.12) | |
EV/FCF |
(6.15) | (5.31) | (12.08) | (14.82) | |
Quick Ratio |
6.46 | 6.31 | 4.91 | 4.23 | |
Current Ratio |
6.76 | 6.61 | 5.28 | 4.53 | |
Net Debt/EBITDA |
10.15 | 7.54 | 6.60 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.23 | 0.22 | 0.24 | 0.30 | |
Operating CF/Net income |
0.93 | 0.75 | 0.81 | 0.80 | |
Capex/Depreciation |
(0.05) | (2.47) | (2.81) | — | |
Interest Coverage |
(388.71) | (684.28) | (907.86) | (986.61) | |
Research and Development Expense of Revenue |
75.36% | 93.97% | 73.07% | 62.80% | |
Selling, General and Administrative Expense of Revenue |
81.26% | 115.71% | 98.39% | 101.63% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
13.25% | 16.50% | 17.81% | 15.28% | |
Graham Net Nets |
0.27 | 0.28 | 0.12 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.43%) | (16.01%) | (8.13%) | (7.19%) | |
Free Cash Flow Yield |
(11.18%) | (12.74%) | (7.14%) | (6.08%) | |
Revenue per Share |
0.19 | 0.15 | 0.21 | 0.24 | |
Operating CF per Share |
(0.25) | (0.22) | (0.24) | (0.25) | |
Capex per Share |
0.00 | (0.03) | (0.04) | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.25) | (0.28) | (0.25) | |
Cash per Share |
2.69 | 2.24 | 2.02 | 1.78 | |
Shareholders Equity per Share |
2.93 | 2.45 | 2.23 | 1.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.93 | 2.45 | 2.23 | 1.98 | |
Free Cash Flow |
(22.32) | (25.55) | (29.55) | (27.07) | |
Working Capital |
228.32 | 219.15 | 198.67 | 173.78 | |
Capital Expenditures |
(0.08) | (3.07) | (3.78) | — | |
Net Current Asset Value |
194.97 | 187.57 | 168.08 | 144.12 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.20 | 0.17 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.17 | 12.00 | 12.53 | 16.21 | |
Average Payables |
9.69 | 10.30 | 12.97 | 12.82 | |
Average Inventory |
6.04 | 5.93 | 7.54 | 6.02 | |
Average Assets |
302.22 | 299.35 | 285.41 | 267.22 | |
Average Common Equity |
232.07 | 231.06 | 213.00 | 192.04 |
Columns are period end dates · fundamentals updated 4 Nov 2026